Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016:2016:3806157.
doi: 10.1155/2016/3806157. Epub 2015 Nov 30.

Getting to NO Alzheimer's Disease: Neuroprotection versus Neurotoxicity Mediated by Nitric Oxide

Rachelle Balez  1 , Lezanne Ooi  1
Affiliations
Review

Getting to NO Alzheimer's Disease: Neuroprotection versus Neurotoxicity Mediated by Nitric Oxide

Rachelle Balez et al. Oxid Med Cell Longev. 2016.

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder involving the loss of neurons in the brain which leads to progressive memory loss and behavioral changes. To date, there are only limited medications for AD and no known cure. Nitric oxide (NO) has long been considered part of the neurotoxic insult caused by neuroinflammation in the Alzheimer's brain. However, focusing on early developments, prior to the appearance of cognitive symptoms, is changing that perception. This has highlighted a compensatory, neuroprotective role for NO that protects synapses by increasing neuronal excitability. A potential mechanism for augmentation of excitability by NO is via modulation of voltage-gated potassium channel activity (Kv7 and Kv2). Identification of the ionic mechanisms and signaling pathways that mediate this protection is an important next step for the field. Harnessing the protective role of NO and related signaling pathways could provide a therapeutic avenue that prevents synapse loss early in disease.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Reitz C., Brayne C., Mayeux R. Epidemiology of Alzheimer disease. Nature Reviews Neurology. 2011;7(3):137–152. doi: 10.1038/nrneurol.2011.2. - DOI - PMC - PubMed
    1. Wimo A., Jönsson L., Bond J., Prince M., Winblad B. The worldwide economic impact of dementia 2010. Alzheimer's and Dementia. 2013;9(1):1–11. doi: 10.1016/j.jalz.2012.11.006. - DOI - PubMed
    1. Thies W., Bleiler L. 2012 Alzheimer's disease facts and figures. Alzheimer's and Dementia. 2012;8(2):131–168. doi: 10.1016/j.jalz.2012.02.001. - DOI - PubMed
    1. Casey D. A., Antimisiaris D., O'Brien J. Drugs for Alzheimer's disease: are they effective? Pharmacology & Therapeutics. 2010;35(4):208–211. - PMC - PubMed
    1. Poirier J., Davignon J., Bouthillier D., Kogan S., Bertrand P., Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. The Lancet. 1993;342(8873):697–699. doi: 10.1016/0140-6736(93)91705-q. - DOI - PubMed

MeSH terms